{"protocolSection": {"identificationModule": {"nctId": "NCT03326063", "orgStudyIdInfo": {"id": "2017P001523"}, "organization": {"fullName": "Brigham and Women's Hospital", "class": "OTHER"}, "briefTitle": "Therapeutic Control of Aspirin-Exacerbated Respiratory Disease With Ifetroban", "officialTitle": "Therapeutic Control of Aspirin-Exacerbated Respiratory Disease"}, "statusModule": {"statusVerifiedDate": "2023-06", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2018-04-26", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2022-03-30", "type": "ACTUAL"}, "completionDateStruct": {"date": "2023-04-15", "type": "ACTUAL"}, "studyFirstSubmitDate": "2017-08-16", "studyFirstSubmitQcDate": "2017-10-25", "studyFirstPostDateStruct": {"date": "2017-10-30", "type": "ACTUAL"}, "resultsFirstSubmitDate": "2023-05-22", "resultsFirstSubmitQcDate": "2023-06-21", "resultsFirstPostDateStruct": {"date": "2023-07-14", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2023-06-21", "lastUpdatePostDateStruct": {"date": "2023-07-14", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Elliot Israel, MD", "investigatorTitle": "Director of Asthma Research Center", "investigatorAffiliation": "Brigham and Women's Hospital"}, "leadSponsor": {"name": "Brigham and Women's Hospital", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": true, "isFdaRegulatedDrug": true, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "The overall aim of the study is to determine the efficacy of oral ifetroban, a novel antagonist of T prostanoid (TP) receptors, as a treatment for patients with aspirin-exacerbated respiratory disease (AERD).", "detailedDescription": "The protocol involves a 4-week, double-blind, placebo-controlled parallel-design trial of oral ifetroban in patients with AERD. At the end of the 4-week treatment phase (ifetroban or placebo) each subject will undergo a graded oral aspirin desensitization procedure in order to initiate high-dose aspirin therapy, which is standard-of-care at our institution and is the only available therapy known to modify the course of AERD."}, "conditionsModule": {"conditions": ["Nasal Polyps", "Asthma, Aspirin-Induced", "Aspirin-exacerbated Respiratory Disease", "Aspirin-Sensitive Asthma With Nasal Polyps"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 38, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Ifetroban", "type": "ACTIVE_COMPARATOR", "description": "Subjects will be randomized to receive ifetroban (200 mg dose per day) for 4 weeks.", "interventionNames": ["Drug: Ifetroban"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Subjects will be randomized to receive placebo for 4 weeks.", "interventionNames": ["Drug: Placebo"]}], "interventions": [{"type": "DRUG", "name": "Ifetroban", "description": "4-week, double-blind, placebo-controlled parallel-design trial of oral ifetroban (a TP receptor antagonist) in patients with AERD", "armGroupLabels": ["Ifetroban"], "otherNames": ["ifetroban sodium"]}, {"type": "DRUG", "name": "Placebo", "description": "4-week, double-blind, placebo-controlled parallel-design trial of oral ifetroban (a TP receptor antagonist) in patients with AERD", "armGroupLabels": ["Placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Provocative Dose 2 (PD2) During Aspirin Challenge", "description": "The calculated dose of aspirin that induces an increase in the Total Nasal Symptom Score (TNSS) of 2 from the pre-aspirin challenge value, \"PD2\"\n\nTNSS: A higher TNSS score suggests more severe symptoms, on a scale from 0-65 PD2: A higher PD2 suggests that the patient's threshold of reactivity of aspirin was higher", "timeFrame": "6 weeks from screening visit ( at visit 2)"}], "secondaryOutcomes": [{"measure": "Percentage Change From Baseline of FEV1 During Aspirin Challenge (Bronchoconstriction)", "description": "Severity of bronchoconstriction during the aspirin-induced reaction at Visit 2, compared between patients on placebo vs ifetroban, with the changes also analyzed with provocative aspirin dose as a covariate. Measured by an aspirin-induced decrease in FEV1.", "timeFrame": "At Visit 2. The change in FEV1 from the morning baseline to the aspirin-induced lowest value in FEV1 during reaction to aspirin challenge later that same day."}, {"measure": "Aspirin-induced Leukotriene E4 (LTE4) Levels", "description": "Increase of urinary levels of LTE4 during aspirin-induced reaction from Visit 2 pre-aspirin levels, compared between patients on placebo vs ifetroban, with the changes also analyzed with provocative aspirin dose as a covariate. LTE4 levels were calculated in a specialized laboratory.", "timeFrame": "Visit 2. The change in LTE4 levels from the morning baseline to the aspirin-induced highest value in LTE4 during reaction to aspirin challenge that same day."}, {"measure": "Change in Chronic Disease Control by Measurement of Lung Function Through FEV1", "description": "Change from Visit 1 in baseline FEV1,compared between patients on placebo vs ifetroban.", "timeFrame": "1 month (between Visit 1 and Visit 2)"}, {"measure": "Change in Chronic Disease by Measurement of Asthma Control Through Asthma Control Questionnaire (ACQ) Score", "description": "Change from Visit 1 in baseline ACQ (Asthma Control Questionnaire) score, compared between patients on placebo vs ifetroban.\n\nACQ is a patient-reported questionnaire measurement of asthma control from 0-6, where lower scores suggest better asthma control. The score is the average result of the answer choices picked by the patient.", "timeFrame": "1 month (between Visit 1 and Visit 2)"}, {"measure": "Clinical Improvement of Chronic Disease - Sino-Nasal Outcome Test (SNOT-22) Score", "description": "Change from Visit 1 in baseline SNOT-22 score at Visit 2, compared between patients on placebo vs ifetroban.\n\nThe SNOT-22 is a patient-reported questionnaire with a summed scale that goes from 0-110 and a lower score suggests better sinonasal control.", "timeFrame": "1 month (between Visit 1 and Visit 2)"}, {"measure": "Fractional Exhaled Nitric Oxide (FeNO)", "description": "Change from Visit 1 in baseline FeNO levels at Visit 2, compared between patients on placebo vs ifetroban.", "timeFrame": "1 month (between Visit 1 and Visit 2)"}], "otherOutcomes": [{"measure": "Percent Change in Urinary Eicosanoid (TXB2 and LTE4) Levels", "description": "Change in levels of other urinary eicosanoids,from Visit 1 to Visit 2 pre-aspirin challenge and Visit 2 pre-aspirin to during the aspirin-induced reaction at Visit 2, compared between patients on placebo vs ifetroban, with the changes also analyzed with provocative aspirin dose as a covariate. Measurements include urinary thromboxane B2 (TXB2) and LTE4.", "timeFrame": "1 month (between Visit 1 and Visit 2) and 6 weeks from screening visit ( at visit 2)"}, {"measure": "Nasal Eicosanoid Changes", "description": "Change in levels of nasal eicosanoids, from Visit 1 to Visit 2 pre-aspirin challenge and Visit 2 pre-aspirin to during the aspirin-induced reaction at Visit 2, compared between patients on placebo vs ifetroban, with the changes also analyzed with provocative aspirin dose as a covariate.", "timeFrame": "1 month (between Visit 1 and Visit 2) and 6 weeks from screening visit ( at visit 2)"}, {"measure": "Plasma/Serum Tryptase Changes", "description": "Change in levels of plasma/serum tryptase, from Visit 1 to Visit 2 pre-aspirin challenge and Visit 2 pre-aspirin to during the aspirin-induced reaction at Visit 2, compared between patients on placebo vs ifetroban, with the changes also analyzed with provocative aspirin dose as a covariate.", "timeFrame": "1 month (between Visit 1 and Visit 2) and 6 weeks from screening visit ( at visit 2)"}, {"measure": "Nasal Tryptase Changes", "description": "Change in levels of nasal tryptase, from Visit 1 to Visit 2 pre-aspirin challenge and Visit 2 pre-aspirin to during the aspirin-induced reaction at Visit 2, compared between patients on placebo vs ifetroban, with the changes also analyzed with provocative aspirin dose as a covariate.", "timeFrame": "1 month (between Visit 1 and Visit 2) and 6 weeks from screening visit ( at visit 2)"}, {"measure": "Platelet Activation - Numbers of Activated Platelets", "description": "Change in numbers of activated platelets in the peripheral blood from Visit 1 to Visit 2 baseline (pre-aspirin administration) and during the aspirin-induced reaction at Visit 2 from Visit 2 baseline, compared between patients on placebo vs ifetroban, with the changes also analyzed with provocative aspirin dose as a covariate.", "timeFrame": "1 month (between Visit 1 and Visit 2) and during aspirin challenge visit"}, {"measure": "Platelet Activation - Percentages of Activated Platelets", "description": "Change in percentages of activated platelets in the peripheral blood from Visit 1 to Visit 2 baseline (pre-aspirin administration) and during the aspirin-induced reaction at Visit 2 from Visit 2 baseline, compared between patients on placebo vs ifetroban, with the changes also analyzed with provocative aspirin dose as a covariate.", "timeFrame": "1 month (between Visit 1 and Visit 2) and 6 weeks from screening visit ( at visit 2)"}, {"measure": "Platelet Activation - Numbers of Platelet-leukocyte Aggregates", "description": "Change in numbers of platelet-leukocyte aggregates in the peripheral blood from Visit 1 to Visit 2 baseline (pre-aspirin administration) and during the aspirin-induced reaction at Visit 2 from Visit 2 baseline, compared between patients on placebo vs ifetroban, with the changes also analyzed with provocative aspirin dose as a covariate.", "timeFrame": "1 month (between Visit 1 and Visit 2) and 6 weeks from screening visit ( at visit 2)"}, {"measure": "Platelet Activation - Percentages of Platelet-leukocyte Aggregates", "description": "Change in percentages of platelet-leukocyte aggregates in the peripheral blood from Visit 1 to Visit 2 baseline (pre-aspirin administration) and during the aspirin-induced reaction at Visit 2 from Visit 2 baseline, compared between patients on placebo vs ifetroban, with the changes also analyzed with provocative aspirin dose as a covariate.", "timeFrame": "1 month (between Visit 1 and Visit 2) and 6 weeks from screening visit ( at visit 2)"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n1. History of AERD, defined as meeting the diagnostic triad with:\n\n   * History of physician-diagnosed asthma and\n   * History of physician-diagnosed nasal polyposis and\n   * History of pathognomonic reactions aspirin or other nonselective cyclooxygenase (COX) inhibitors.\n2. Stable asthma (post-bronchodilator forced expiratory volume at one second (FEV1) of \u226570%, no glucocorticoid burst for at least 2 weeks prior to Visit 1, and no hospitalizations or ER visits for asthma for at least the prior 6 months)\n3. Age between 18 and 70 years\n4. No current smoking (not more than one instance of smoking in the last 3 months)\n5. Non-pregnant\n\nExclusion Criteria:\n\n1. Hypersensitivity to montelukast\n2. Current use of zileuton\n3. History of bleeding diathesis or use of anticoagulant or antiplatelet drugs\n4. Current use of any NSAIDs aside from the aspirin provided during the study\n5. Current use of beta blockers\n6. Use of any biologics within the last 4 months prior to initiating the study", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "70 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Elliot Israel, MD", "affiliation": "Brigham and Women's Hospital", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Asthma Research Center, Brigham and Women's Hospital", "city": "Boston", "state": "Massachusetts", "zip": "02115", "country": "United States", "geoPoint": {"lat": 42.35843, "lon": -71.05977}}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "36 of whom underwent randomization per protocol, and 35 of whom completed the trial and were analyzed.", "recruitmentDetails": "A total of 38 potential participants were screened at Brigham and Women's Hospital.", "groups": [{"id": "FG000", "title": "Ifetroban", "description": "Subjects will be randomized to receive ifetroban (200 mg dose per day) for 4 weeks.\n\nIfetroban: 4-week, double-blind, placebo-controlled parallel-design trial of oral ifetroban (a thromboxane-prostanoid (TP) receptor antagonist) in patients with aspirin-exacerbated respiratory disease (AERD)\n\nPatients were then challenged to aspirin at ascending doses, starting at 40.5mg, 81mg, 162mg, and 325mg, given every 90 minutes until a reaction was provoked."}, {"id": "FG001", "title": "Placebo", "description": "Subjects will be randomized to receive placebo for 4 weeks.\n\nPlacebo: 4-week, double-blind, placebo-controlled parallel-design trial of oral ifetroban (a thromboxane-prostanoid (TP) receptor antagonist) in patients with aspirin-exacerbated respiratory disease (AERD)\n\nPatients were then challenged to aspirin at ascending doses, starting at 40.5mg, 81mg, 162mg, and 325mg, given every 90 minutes until a reaction was provoked."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "18"}, {"groupId": "FG001", "numSubjects": "18"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "17"}, {"groupId": "FG001", "numSubjects": "18"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}], "dropWithdraws": [{"type": "COVID pandemic: subject recalled to her country", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Ifetroban", "description": "Subjects will be randomized to receive ifetroban (200 mg dose per day) for 4 weeks.\n\nIfetroban: 4-week, double-blind, placebo-controlled parallel-design trial of oral ifetroban (a TP receptor antagonist) in patients with AERD"}, {"id": "BG001", "title": "Placebo", "description": "Subjects will be randomized to receive placebo for 4 weeks.\n\nPlacebo: 4-week, double-blind, placebo-controlled parallel-design trial of oral ifetroban (a TP receptor antagonist) in patients with AERD"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "18"}, {"groupId": "BG001", "value": "18"}, {"groupId": "BG002", "value": "36"}]}], "measures": [{"title": "Age, Categorical", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "18"}, {"groupId": "BG001", "value": "18"}, {"groupId": "BG002", "value": "36"}]}], "categories": [{"title": "<=18 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Between 18 and 65 years", "measurements": [{"groupId": "BG000", "value": "18"}, {"groupId": "BG001", "value": "17"}, {"groupId": "BG002", "value": "35"}]}, {"title": ">=65 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "1"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "18"}, {"groupId": "BG001", "value": "18"}, {"groupId": "BG002", "value": "36"}]}], "categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "11"}, {"groupId": "BG001", "value": "7"}, {"groupId": "BG002", "value": "18"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "7"}, {"groupId": "BG001", "value": "11"}, {"groupId": "BG002", "value": "18"}]}]}]}, {"title": "Ethnicity (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "18"}, {"groupId": "BG001", "value": "18"}, {"groupId": "BG002", "value": "36"}]}], "categories": [{"title": "Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "4"}]}, {"title": "Not Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "16"}, {"groupId": "BG001", "value": "16"}, {"groupId": "BG002", "value": "32"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "18"}, {"groupId": "BG001", "value": "18"}, {"groupId": "BG002", "value": "36"}]}], "categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "1"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "2"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "16"}, {"groupId": "BG001", "value": "16"}, {"groupId": "BG002", "value": "32"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "1"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "United States", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "18"}, {"groupId": "BG001", "value": "18"}, {"groupId": "BG002", "value": "36"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "18"}, {"groupId": "BG001", "value": "18"}, {"groupId": "BG002", "value": "36"}]}]}]}, {"title": "Provocative Dose 2 (PD2) During Aspirin Challenge", "populationDescription": "36 subjects were randomized, but 1 subject in ifetroban arm was lost to follow-up and did not complete primary outcome for analysis.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mg", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "17"}, {"groupId": "BG001", "value": "18"}, {"groupId": "BG002", "value": "35"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "121", "spread": "48"}, {"groupId": "BG001", "value": "142", "spread": "46"}, {"groupId": "BG002", "value": "132", "spread": "47"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Provocative Dose 2 (PD2) During Aspirin Challenge", "description": "The calculated dose of aspirin that induces an increase in the Total Nasal Symptom Score (TNSS) of 2 from the pre-aspirin challenge value, \"PD2\"\n\nTNSS: A higher TNSS score suggests more severe symptoms, on a scale from 0-65 PD2: A higher PD2 suggests that the patient's threshold of reactivity of aspirin was higher", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mg", "timeFrame": "6 weeks from screening visit ( at visit 2)", "groups": [{"id": "OG000", "title": "Ifetroban", "description": "Subjects will be randomized to receive ifetroban (200 mg dose per day) for 4 weeks.\n\nIfetroban: 4-week, double-blind, placebo-controlled parallel-design trial of oral ifetroban (a TP receptor antagonist) in patients with AERD"}, {"id": "OG001", "title": "Placebo", "description": "Subjects will be randomized to receive placebo for 4 weeks.\n\nPlacebo: 4-week, double-blind, placebo-controlled parallel-design trial of oral ifetroban (a TP receptor antagonist) in patients with AERD"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "17"}, {"groupId": "OG001", "value": "18"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "121", "spread": "48"}, {"groupId": "OG001", "value": "142", "spread": "46"}]}]}]}, {"type": "SECONDARY", "title": "Percentage Change From Baseline of FEV1 During Aspirin Challenge (Bronchoconstriction)", "description": "Severity of bronchoconstriction during the aspirin-induced reaction at Visit 2, compared between patients on placebo vs ifetroban, with the changes also analyzed with provocative aspirin dose as a covariate. Measured by an aspirin-induced decrease in FEV1.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percentage change from baseline", "timeFrame": "At Visit 2. The change in FEV1 from the morning baseline to the aspirin-induced lowest value in FEV1 during reaction to aspirin challenge later that same day.", "groups": [{"id": "OG000", "title": "Ifetroban", "description": "Subjects randomized to receive Ifetroban."}, {"id": "OG001", "title": "Placebo", "description": "Subjects randomized to receive placebo."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "17"}, {"groupId": "OG001", "value": "18"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-18.8", "spread": "3.6"}, {"groupId": "OG001", "value": "-8.4", "spread": "2.1"}]}]}]}, {"type": "SECONDARY", "title": "Aspirin-induced Leukotriene E4 (LTE4) Levels", "description": "Increase of urinary levels of LTE4 during aspirin-induced reaction from Visit 2 pre-aspirin levels, compared between patients on placebo vs ifetroban, with the changes also analyzed with provocative aspirin dose as a covariate. LTE4 levels were calculated in a specialized laboratory.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng/mg creatinine", "timeFrame": "Visit 2. The change in LTE4 levels from the morning baseline to the aspirin-induced highest value in LTE4 during reaction to aspirin challenge that same day.", "groups": [{"id": "OG000", "title": "Ifetroban", "description": "Subjects randomized to receive Ifetroban."}, {"id": "OG001", "title": "Placebo", "description": "Subjects randomized to receive placebo."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "17"}, {"groupId": "OG001", "value": "18"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.72", "spread": "0.30"}, {"groupId": "OG001", "value": "0.15", "spread": "0.10"}]}]}]}, {"type": "SECONDARY", "title": "Change in Chronic Disease Control by Measurement of Lung Function Through FEV1", "description": "Change from Visit 1 in baseline FEV1,compared between patients on placebo vs ifetroban.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percent change from baseline", "timeFrame": "1 month (between Visit 1 and Visit 2)", "groups": [{"id": "OG000", "title": "Ifetroban", "description": "Subjects randomized to receive Ifetroban."}, {"id": "OG001", "title": "Placebo", "description": "Subjects randomized to receive placebo."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "17"}, {"groupId": "OG001", "value": "18"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.2", "spread": "1.3"}, {"groupId": "OG001", "value": "-0.5", "spread": "1.2"}]}]}]}, {"type": "SECONDARY", "title": "Change in Chronic Disease by Measurement of Asthma Control Through Asthma Control Questionnaire (ACQ) Score", "description": "Change from Visit 1 in baseline ACQ (Asthma Control Questionnaire) score, compared between patients on placebo vs ifetroban.\n\nACQ is a patient-reported questionnaire measurement of asthma control from 0-6, where lower scores suggest better asthma control. The score is the average result of the answer choices picked by the patient.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "scores on a scale", "timeFrame": "1 month (between Visit 1 and Visit 2)", "groups": [{"id": "OG000", "title": "Ifetroban", "description": "Subjects randomized to receive Ifetroban."}, {"id": "OG001", "title": "Placebo", "description": "Subjects randomized to receive placebo."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "17"}, {"groupId": "OG001", "value": "18"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.17", "spread": "0.16"}, {"groupId": "OG001", "value": "-0.03", "spread": "0.11"}]}]}]}, {"type": "SECONDARY", "title": "Clinical Improvement of Chronic Disease - Sino-Nasal Outcome Test (SNOT-22) Score", "description": "Change from Visit 1 in baseline SNOT-22 score at Visit 2, compared between patients on placebo vs ifetroban.\n\nThe SNOT-22 is a patient-reported questionnaire with a summed scale that goes from 0-110 and a lower score suggests better sinonasal control.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "scores on a scale", "timeFrame": "1 month (between Visit 1 and Visit 2)", "groups": [{"id": "OG000", "title": "Ifetroban", "description": "Subjects randomized to receive Ifetroban."}, {"id": "OG001", "title": "Placebo", "description": "Subjects randomized to receive placebo."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "17"}, {"groupId": "OG001", "value": "18"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.5", "spread": "3.0"}, {"groupId": "OG001", "value": "-2.0", "spread": "2.3"}]}]}]}, {"type": "SECONDARY", "title": "Fractional Exhaled Nitric Oxide (FeNO)", "description": "Change from Visit 1 in baseline FeNO levels at Visit 2, compared between patients on placebo vs ifetroban.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "parts per billion", "timeFrame": "1 month (between Visit 1 and Visit 2)", "groups": [{"id": "OG000", "title": "Ifetroban", "description": "Subjects randomized to receive Ifetroban."}, {"id": "OG001", "title": "Placebo", "description": "Subjects randomized to receive placebo."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "17"}, {"groupId": "OG001", "value": "18"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "7.9", "spread": "9.0"}, {"groupId": "OG001", "value": "-3.4", "spread": "3.0"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Percent Change in Urinary Eicosanoid (TXB2 and LTE4) Levels", "description": "Change in levels of other urinary eicosanoids,from Visit 1 to Visit 2 pre-aspirin challenge and Visit 2 pre-aspirin to during the aspirin-induced reaction at Visit 2, compared between patients on placebo vs ifetroban, with the changes also analyzed with provocative aspirin dose as a covariate. Measurements include urinary thromboxane B2 (TXB2) and LTE4.", "reportingStatus": "NOT_POSTED", "timeFrame": "1 month (between Visit 1 and Visit 2) and 6 weeks from screening visit ( at visit 2)", "denomUnitsSelected": "Participants"}, {"type": "OTHER_PRE_SPECIFIED", "title": "Nasal Eicosanoid Changes", "description": "Change in levels of nasal eicosanoids, from Visit 1 to Visit 2 pre-aspirin challenge and Visit 2 pre-aspirin to during the aspirin-induced reaction at Visit 2, compared between patients on placebo vs ifetroban, with the changes also analyzed with provocative aspirin dose as a covariate.", "reportingStatus": "NOT_POSTED", "timeFrame": "1 month (between Visit 1 and Visit 2) and 6 weeks from screening visit ( at visit 2)", "denomUnitsSelected": "Participants"}, {"type": "OTHER_PRE_SPECIFIED", "title": "Plasma/Serum Tryptase Changes", "description": "Change in levels of plasma/serum tryptase, from Visit 1 to Visit 2 pre-aspirin challenge and Visit 2 pre-aspirin to during the aspirin-induced reaction at Visit 2, compared between patients on placebo vs ifetroban, with the changes also analyzed with provocative aspirin dose as a covariate.", "reportingStatus": "NOT_POSTED", "timeFrame": "1 month (between Visit 1 and Visit 2) and 6 weeks from screening visit ( at visit 2)", "denomUnitsSelected": "Participants"}, {"type": "OTHER_PRE_SPECIFIED", "title": "Nasal Tryptase Changes", "description": "Change in levels of nasal tryptase, from Visit 1 to Visit 2 pre-aspirin challenge and Visit 2 pre-aspirin to during the aspirin-induced reaction at Visit 2, compared between patients on placebo vs ifetroban, with the changes also analyzed with provocative aspirin dose as a covariate.", "reportingStatus": "NOT_POSTED", "timeFrame": "1 month (between Visit 1 and Visit 2) and 6 weeks from screening visit ( at visit 2)", "denomUnitsSelected": "Participants"}, {"type": "OTHER_PRE_SPECIFIED", "title": "Platelet Activation - Numbers of Activated Platelets", "description": "Change in numbers of activated platelets in the peripheral blood from Visit 1 to Visit 2 baseline (pre-aspirin administration) and during the aspirin-induced reaction at Visit 2 from Visit 2 baseline, compared between patients on placebo vs ifetroban, with the changes also analyzed with provocative aspirin dose as a covariate.", "reportingStatus": "NOT_POSTED", "timeFrame": "1 month (between Visit 1 and Visit 2) and during aspirin challenge visit", "denomUnitsSelected": "Participants"}, {"type": "OTHER_PRE_SPECIFIED", "title": "Platelet Activation - Percentages of Activated Platelets", "description": "Change in percentages of activated platelets in the peripheral blood from Visit 1 to Visit 2 baseline (pre-aspirin administration) and during the aspirin-induced reaction at Visit 2 from Visit 2 baseline, compared between patients on placebo vs ifetroban, with the changes also analyzed with provocative aspirin dose as a covariate.", "reportingStatus": "NOT_POSTED", "timeFrame": "1 month (between Visit 1 and Visit 2) and 6 weeks from screening visit ( at visit 2)", "denomUnitsSelected": "Participants"}, {"type": "OTHER_PRE_SPECIFIED", "title": "Platelet Activation - Numbers of Platelet-leukocyte Aggregates", "description": "Change in numbers of platelet-leukocyte aggregates in the peripheral blood from Visit 1 to Visit 2 baseline (pre-aspirin administration) and during the aspirin-induced reaction at Visit 2 from Visit 2 baseline, compared between patients on placebo vs ifetroban, with the changes also analyzed with provocative aspirin dose as a covariate.", "reportingStatus": "NOT_POSTED", "timeFrame": "1 month (between Visit 1 and Visit 2) and 6 weeks from screening visit ( at visit 2)", "denomUnitsSelected": "Participants"}, {"type": "OTHER_PRE_SPECIFIED", "title": "Platelet Activation - Percentages of Platelet-leukocyte Aggregates", "description": "Change in percentages of platelet-leukocyte aggregates in the peripheral blood from Visit 1 to Visit 2 baseline (pre-aspirin administration) and during the aspirin-induced reaction at Visit 2 from Visit 2 baseline, compared between patients on placebo vs ifetroban, with the changes also analyzed with provocative aspirin dose as a covariate.", "reportingStatus": "NOT_POSTED", "timeFrame": "1 month (between Visit 1 and Visit 2) and 6 weeks from screening visit ( at visit 2)", "denomUnitsSelected": "Participants"}]}, "adverseEventsModule": {"frequencyThreshold": "0", "timeFrame": "Adverse events were reported from the time of randomized subject enrollment through study completion, about 8 weeks.", "eventGroups": [{"id": "EG000", "title": "Placebo", "description": "Subjects with AERD who received Placebo", "deathsNumAffected": 0, "deathsNumAtRisk": 18, "seriousNumAffected": 0, "seriousNumAtRisk": 18, "otherNumAffected": 11, "otherNumAtRisk": 18}, {"id": "EG001", "title": "Ifetroban", "description": "Subjects with AERD who received Ifetroban", "deathsNumAffected": 0, "deathsNumAtRisk": 18, "seriousNumAffected": 0, "seriousNumAtRisk": 18, "otherNumAffected": 12, "otherNumAtRisk": 18}], "otherEvents": [{"term": "Upper Respiratory Tract Infection/Sinusitis, Grade 2", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 18}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}]}, {"term": "Pregnant partner", "organSystem": "Pregnancy, puerperium and perinatal conditions", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}]}, {"term": "Rash, maculo-papular, Grade 1", "organSystem": "Skin and subcutaneous tissue disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 18}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}]}, {"term": "Ear Pain, Grade 1", "organSystem": "Ear and labyrinth disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}]}, {"term": "Stomach Pain, Grade 1", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "Includes vomiting, diarrhea, and/or constipation", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}]}, {"term": "Eye disorder- Stye, Grade 1", "organSystem": "Eye disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 18}]}, {"term": "Systemic reaction to aspirin challenge with extrapulmonary symptoms", "organSystem": "Injury, poisoning and procedural complications", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 18}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 18}]}, {"term": "Lung Infection (influenza B-related pneumonia), Grade 2", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 18}]}, {"term": "Wheezing, Grade 1", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 18}]}, {"term": "Sinus disorder (bloody nose), Grade 1", "organSystem": "Blood and lymphatic system disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 18}]}, {"term": "Bruising, Grade 1", "organSystem": "Blood and lymphatic system disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 18}]}, {"term": "Otitis Media, Grade 2", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 18}]}, {"term": "Constipation, Grade 1", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 18}]}, {"term": "Nasal Congestion, Grade 1", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}]}, {"term": "Lower gastrointestinal hemorrhage, Grade 1", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}]}, {"term": "Vomiting, Grade 1", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 18}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": false}, "pointOfContact": {"title": "Tanya Laidlaw, MD", "organization": "Brigham and Women's Hospital", "email": "tlaidlaw@bwh.harvard.edu", "phone": "617-525-1034"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot_SAP", "hasProtocol": true, "hasSap": true, "hasIcf": false, "label": "Study Protocol and Statistical Analysis Plan", "date": "2020-07-24", "uploadDate": "2023-05-22T11:31", "filename": "Prot_SAP_000.pdf", "size": 1424137}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "submissionTracking": {"firstMcpInfo": {"postDateStruct": {"date": "2023-06-18", "type": "ACTUAL"}}}}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000012120", "term": "Respiration Disorders"}, {"id": "D000009298", "term": "Nasal Polyps"}, {"id": "D000055963", "term": "Asthma, Aspirin-Induced"}, {"id": "D000011127", "term": "Polyps"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}, {"id": "D000020763", "term": "Pathological Conditions, Anatomical"}, {"id": "D000009668", "term": "Nose Diseases"}, {"id": "D000010038", "term": "Otorhinolaryngologic Diseases"}, {"id": "D000004342", "term": "Drug Hypersensitivity"}, {"id": "D000064420", "term": "Drug-Related Side Effects and Adverse Reactions"}, {"id": "D000064419", "term": "Chemically-Induced Disorders"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "asFound": "Respiratory Disease", "relevance": "HIGH"}, {"id": "M14957", "name": "Respiration Disorders", "asFound": "Respiratory Disease", "relevance": "HIGH"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14011", "name": "Polyps", "asFound": "Polyps", "relevance": "HIGH"}, {"id": "M12249", "name": "Nasal Polyps", "asFound": "Nasal Polyps", "relevance": "HIGH"}, {"id": "M28406", "name": "Asthma, Aspirin-Induced", "asFound": "Asthma, Aspirin-Induced", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}, {"id": "M22519", "name": "Pathological Conditions, Anatomical", "relevance": "LOW"}, {"id": "M12604", "name": "Nose Diseases", "relevance": "LOW"}, {"id": "M12961", "name": "Otorhinolaryngologic Diseases", "relevance": "LOW"}, {"id": "M7517", "name": "Drug Hypersensitivity", "relevance": "LOW"}, {"id": "M30303", "name": "Drug-Related Side Effects and Adverse Reactions", "relevance": "LOW"}, {"id": "M30302", "name": "Chemically-Induced Disorders", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "BC09", "name": "Ear, Nose, and Throat Diseases"}, {"abbrev": "BC25", "name": "Substance Related Disorders"}]}, "interventionBrowseModule": {"meshes": [{"id": "C000078904", "term": "Ifetroban"}], "ancestors": [{"id": "D000010975", "term": "Platelet Aggregation Inhibitors"}], "browseLeaves": [{"id": "M4548", "name": "Aspirin", "relevance": "LOW"}, {"id": "M228666", "name": "Ifetroban", "asFound": "CGI", "relevance": "HIGH"}, {"id": "M13865", "name": "Platelet Aggregation Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Antipy", "name": "Antipyretics"}, {"abbrev": "Infl", "name": "Anti-Inflammatory Agents"}, {"abbrev": "ARhu", "name": "Antirheumatic Agents"}, {"abbrev": "FiAg", "name": "Fibrinolytic Agents"}, {"abbrev": "Analg", "name": "Analgesics"}, {"abbrev": "PlAggInh", "name": "Platelet Aggregation Inhibitors"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}